Form 4: Lexaria Bioscience Corp. Director Baljinder Bhullar Reports Transaction
SEC Form 4 Filing
Director Baljinder Bhullar reports a transaction involving Lexaria Bioscience Corp. shares and stock options.
Summary
- On May 15, 2025, Baljinder Bhullar, a director of Lexaria Bioscience Corp., reported a transaction.
- Bhullar disposed of 13,000 common shares.
- Bhullar acquired 11,000 stock options with an exercise price of $1.04, exercisable from May 15, 2025, and expiring on May 15, 2030.
- Following the reported transactions, Bhullar directly owns 11,000 derivative securities (stock options).
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing a director's transaction, indicating a neutral sentiment.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Stakeholder Impact
- The transaction may be of interest to shareholders as it provides insight into the actions of a company director.
Key Dates
| Date | Description |
|---|---|
| 05/15/2025 | Date of Earliest Transaction; Grant Date and Exercisable Date of Stock Options |
| 05/15/2030 | Expiration Date of Stock Options |
| 05/16/2025 | Date of Signature |
Keywords
Form 4, Beneficial Ownership, Director, Stock Options, Common Shares, Transaction, Lexaria Bioscience Corp., LEXX, Bhullar, Baljinder
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.